港股异动 | 基石药业-B(2616.HK)大涨逾9% 抑制剂普吉华扩展适应症申请获受理
格隆汇4月27日丨基石药业-B(2616.HK)大幅拉升涨9.35%,报10.58港元创2个月新高价,总市值124亿港元。基石药业-B26日公布,选择性RET抑制剂普吉华(普拉替尼胶囊)扩展适应症申请已获中国国家药品监督管理局受理并被纳入优先审评。普吉华是中国首个获批的选择性RET抑制剂,由基石药业合作伙伴Blueprint Medicines公司(NASDAQ:BPMC)开发。公司的普吉华针对甲状腺癌的适应症获得NMPA受理,这比原计划提前了6个月。研究资料显示在RET突变的甲状腺髓样癌和RET融合阳性的甲状腺癌患者中,普吉华表现出优异且持久的疗效以及良好的耐受性。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.